Ana Garcia-Osta

List of Publications by Year
in descending order

51 papers	3,422 citations	159585 30 h-index	189892 50 g-index
52 all docs	52 docs citations	52 times ranked	4760 citing authors

#	Article	IF	Citations
1	A critical role for IGF-II in memory consolidation and enhancement. Nature, 2011, 469, 491-497.	27.8	368
2	Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model. Neuropsychopharmacology, 2009, 34, 1721-1732.	5.4	367
3	Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus, 2012, 22, 1040-1050.	1.9	218
4	Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease. ACS Chemical Neuroscience, 2012, 3, 832-844.	3.5	216
5	Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology. Neuropsychopharmacology, 2010, 35, 1593-1604.	5.4	200
6	Sildenafil restores cognitive function without affecting Î²-amyloid burden in a mouse model of Alzheimer's disease. British Journal of Pharmacology, 2011, 164, 2029-2041.	5.4	159
7	Tadalafil crosses the bloodâ€“brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology, 2013, 64, 114-123.	4.1	143
8	Amyloid beta mediates memory formation. Learning and Memory, 2009, 16, 267-272.	1.3	141
9	Insulinâ€like growth factor 2 reverses memory and synaptic deficits in <scp>APP</scp> transgenic mice. EMBO Molecular Medicine, 2014, 6, 1246-1262.	6.9	114
10	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimerâ€™s Disease Mice. Neuropsychopharmacology, 2017, 42, 524-539.	5.4	86
11	Decreased levels of guanosine 3â€², 5â€²â€monophosphate (c<scp>GMP</scp>) in cerebrospinal fluid (<scp>CSF</scp>) are associated with cognitive decline and amyloid pathology in <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2015, 41, 471-482.	3.2	84
12	MuSK Expressed in the Brain Mediates Cholinergic Responses, Synaptic Plasticity, and Memory Formation. Journal of Neuroscience, 2006, 26, 7919-7932.	3.6	82
13	BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. NeuroReport, 2001, 12, 919-923.	1.2	73
14	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 8967-9004.	6.4	71
15	Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. Mediators of Inflammation, 2015, 2015, 1-17.	3.0	68
16	Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiology of Disease, 2010, 38, 237-245.	4.4	64
17	Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Molecular Therapy - Nucleic Acids, 2019, 16, 26-37.	5.1	64
18	Phenylbutyrate is a Multifaceted Drug that Exerts Neuroprotective Effects and Reverses the AlzheimerÂ´s Disease-like Phenotype of a Commonly Used Mouse Model. Current Pharmaceutical Design, 2013, 19, 5076-5084.	1.9	59

#	Article	IF	Citations
19	Chronic Mild Stress Accelerates the Onset and Progression of the Alzheimer's Disease Phenotype in Tg2576 Mice. Journal of Alzheimer's Disease, 2012, 28, 567-578.	2.6	54
20	Differential Regulation by Methylenedioxymethamphetamine of 5â€Hydroxytryptamine_{1A} Receptor Density and mRNA Expression in Rat Hippocampus, Frontal Cortex, and Brainstem: The Role of Corticosteroids. Journal of Neurochemistry, 1997, 68, 1099-1105.	3.9	52
21	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimerâ€™s disease. Clinical Epigenetics, 2015, 7, 108.	4.1	52
22	Design, synthesis, biological evaluation and inÂvivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 150, 506-524.	5.5	48
23	Disrupting the memory of places induced by drugs of abuse weakens motivational withdrawal in a context-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12345-12350.	7.1	41
24	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid <scp>cGMP</scp> levels. Journal of Neurochemistry, 2016, 136, 403-415.	3.9	41
25	Chronic mild stress in mice promotes cognitive impairment and CDK5-dependent tau hyperphosphorylation. Behavioural Brain Research, 2011, 220, 338-343.	2.2	37
26	Current Animal Models of AlzheimerÃ¢â‚¬â„¢s Disease: Challenges in Translational Research. Frontiers in Neurology, 2014, 5, 182.	2.4	35
27	Dysregulated Postsynaptic Density and Endocytic Zone in the Amygdala of Human Heroin and Cocaine Abusers. Biological Psychiatry, 2011, 69, 245-252.	1.3	32
28	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 149.	3.4	32
29	Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT1A receptors. British Journal of Pharmacology, 1999, 128, 1691-1698.	5.4	31
30	Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease. Current Medicinal Chemistry, 2011, 18, 5545-5553.	2.4	31
31	Epigenetic drugs in Alzheimerâ€™s disease. Biomolecular Concepts, 2013, 4, 433-445.	2.2	30
32	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 638-661.	3.5	30
33	Long-term Phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing A Beta. Frontiers in Bioscience - Elite, 2011, E3, 1375-1384.	1.8	29
34	The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Neuro-Oncology, 2018, 20, 930-941.	1.2	29
35	Discovery of in Vivo Chemical Probes for Treating Alzheimerâ€™s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. ACS Chemical Neuroscience, 2019, 10, 1765-1782.	3.5	28
36	Multitarget Approach for the Treatment of Alzheimerâ€™s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. ACS Chemical Neuroscience, 2019, 10, 4076-4101.	3.5	27

#	Article	IF	Citations
37	Phosphodiesterase Inhibition in Cognitive Decline. Journal of Alzheimer's Disease, 2014, 42, S561-S573.	2.6	24
38	PLA2G4E, a candidate gene for resilience in AlzheimerÂ´s disease and a new target for dementia treatment. Progress in Neurobiology, 2020, 191, 101818.	5.7	23
39	Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, â€œecstasyâ€) in the rat frontal cortex but not in the hippocampus. Molecular Brain Research, 2004, 126, 181-187.	2.3	22
40	Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum. Molecular Brain Research, 2000, 76, 306-314.	2.3	17
41	Synthesis and Evaluation of 13N-Labelled Azo Compounds for Î²-Amyloid Imaging in Mice. Molecular Imaging and Biology, 2014, 16, 538-549.	2.6	14
42	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. Frontiers in Immunology, 2018, 9, 68.	4.8	14
43	GLUT12 Expression in Brain of Mouse Models of Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 798-805.	4.0	14
44	Chronic Mild Stress Assay Leading to Early Onset and Propagation of Alzheimerâ€™s Disease Phenotype in Mouse Models. Methods in Molecular Biology, 2016, 1303, 241-246.	0.9	13
45	Identifying the Main Functional Pathways Associated with Cognitive Resilience to Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 9120.	4.1	13
46	Effect of p-Chloroamphetamine on 5-HT1A and 5-HT7 Serotonin Receptor Expression in Rat Brain. Journal of Neurochemistry, 2008, 74, 1790-1797.	3.9	10
47	Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 11950.	4.1	7
48	Reduced basal and phencyclidine-induced expression of heat shock protein-70 in rat prefrontal cortex by the atypical antipsychotic abaperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 31-36.	4.8	5
49	Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models. Methods in Molecular Biology, 2016, 1303, 117-123.	0.9	5
50	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. Neurotherapeutics, 2018, 15, 742-750.	4.4	5
51	Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease. , 2020, , 213-226.		0